Critics Decry US Bilateral Health Deals With African Nations

Documents analyzed by the advocacy group Public Citizen suggest the Trump administration is pushing terms that require African states to provide the US with viral samples and pathogen information. These agreements explicitly allow the US to share that data with private pharmaceutical companies, yet offer no reciprocal commitment to grant those nations access to the medical tools eventually created from the research. Critics warn this strategy directly undermines the broader equity negotiations currently underway at the World Health Organization, specifically the proposals put forward by the Africa+ Group.

The agreements function by linking the restoration of US health assistance—previously reduced by the administration—to strict conditions regarding disease surveillance and biological exchange. While supporters claim these deals bolster domestic pandemic preparedness and provide essential funding to partner nations, advocates describe the approach as inherently transactional. Peter Maybarduk, director of Public Citizen’s Access to Medicines program, argues that the administration is exploiting the urgent financial needs of African states to bypass multilateral cooperation, leaving individual countries with little leverage against US demands.